[Detection of the markers of hepatites B and C and herpesvirus infection during pregnancy].
OBJECTIVE
Identification of clinico-epidemiologic features of pareneteral hepatites (HB and HC) and herpesvirus infections (cytomegalovirus, CMVand herpes simplexvirus, HSV) duringpregnancy.


METHODS
Two hundred pregnant women as well as 150 women--blood donors who comprised a control group were tested in Cheboksary (Chuvash Republic). There were no persons vaccinated against HB in both groups. Diagnostics of the HB and HC as well as CMV and HSV infections was performed by ELISA--HBsAg, anti-HBs, anti-HBc IgM and IgG, anti-HCV as well as IgM and IgG to CMV and HSV were determined; PCR was used to detect HBV DNA and HCV RNA.


RESULTS
Moderate prevalence of HB and HC markers in pregnant (31% and 3% respectively) and donor women (34% and 2% respectively) as well as widespread prevalence of herpesvirus infections' markers (from 71% to 94.5%) was established. The studied women had no clinical manifestations of HB or HC as well as CMV or HSV infections at the time of the study. The study revealed the following: association between complications of pregnancy and detected markers of HB, HC, and herpesvirus infections according to trimester; detection rate of HBV and HCV markers in combination with CMV and HSV markers in pregnant women; association of pregnancy complications with presence of HB and HC markers with combination of herpesvirus infection markers.


CONCLUSIONS
It was shown that pregnant women with presence of markers of studied infections present a risk group for development of miscarriage threat, inflammatory processes in placenta and amniotic membranes, and untrauterine fetal growth retardation.
Asratian
A A
AA
Danilenko
E D
ED
Kazarian
S M
SM
Chubarov
V V
VV
Mardanly
S G
SG
D015415:Biomarkers / Q000097:blood; D002353:Carrier State / Q000097:blood / Q000453:epidemiology; D015897:Comorbidity; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000097:blood / Q000453:epidemiology*; D004279:DNA, Viral / Q000097:blood; D005260:Female; D016174:Hepacivirus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D006509:Hepatitis B / Q000097:blood / Q000453:epidemiology*; D006510:Hepatitis B Antibodies / Q000097:blood; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000235:genetics / Q000276:immunology / Q000302:isolation & purification; D006526:Hepatitis C / Q000097:blood / Q000453:epidemiology*; D018937:Hepatitis C Antibodies / Q000097:blood; D006561:Herpes Simplex / Q000097:blood / Q000453:epidemiology*; D006801:Humans; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000097:blood / Q000453:epidemiology* / Q000821:virology*; D012367:RNA, Viral / Q000097:blood; D012307:Risk Factors; D012426:Russia / Q000453:epidemiology; D016036:Seroepidemiologic Studies; D018139:Simplexvirus / Q000276:immunology
D015415:Biomarkers; D004279:DNA, Viral; D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D018937:Hepatitis C Antibodies; D012367:RNA, Viral